Drug Profile
Research programme: therapeutics - Maxygen
Latest Information Update: 03 Sep 2013
Price :
$50
*
At a glance
- Originator Maxygen
- Class
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Autoimmune disorders; Haematological disorders; Thrombosis
Most Recent Events
- 31 May 2007 Preclinical trials in Haematological disorders in USA (unspecified route)
- 31 May 2007 Preclinical trials in Thrombosis in USA (unspecified route)
- 31 May 2007 Preclinical trials in Autoimmune disorders in USA (unspecified route)